Muscle wasting in heart failure: An overview

Area of Science:

• Cardiology
• Muscle Physiology
• Molecular Biology

Background:

• Heart failure frequently limits patient exercise capacity, often attributed solely to cardiac dysfunction.
• Skeletal muscle wasting, encompassing sarcopenia and cachexia, significantly impacts functional limitations in heart failure.
• Cachexia, specifically, involves body weight loss alongside muscle mass and function decline.

Purpose of the Study:

• To elucidate the terminology, molecular pathways, and prevalence of muscle wasting in heart failure.
• To explore the clinical implications of muscle wasting on exercise capacity in heart failure patients.
• To review potential therapeutic strategies for addressing muscle wasting in this population.

Main Methods:

• Review of scientific literature on muscle wasting in heart failure.
• Analysis of molecular mechanisms, including anabolic/catabolic imbalance and myocyte apoptosis.
• Examination of clinical data on prevalence and functional outcomes.

Main Results:

• Muscle wasting in heart failure presents as sarcopenia or cachexia, impacting muscle mass, strength, and exercise capacity.
• Key molecular mechanisms involve an imbalance between muscle protein synthesis and degradation, leading to myofibril breakdown and cell death.
• Cachexia is characterized by significant body weight loss, distinguishing it from sarcopenia.

Conclusions:

• Skeletal muscle wasting is a critical, often underestimated, contributor to exercise limitation in heart failure.
• Targeting the molecular pathways of muscle wasting offers potential therapeutic avenues.
• Further research into treatment approaches is warranted to improve patient outcomes.